Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB

This study is a prospective, randomized phase III, to evaluate if in patients with mCRC RAS/BRAF wild type on tumor tissue and RAS mutations on liquid biopsy, treating in first line with antibody anti-VEGF (bevacizumab) plus chemotherapy (FOLFIRI) is superior in terms of PFS compared to standard treatment with antibody anti-EGFR (cetuximab) plus FOLFIRI, and then in patients RAS/BRAF wild type on tumor tissue who develop RAS mutations on liquid biopsy after the beginning of the first line treatment with cetuximab plus FOLFIRI, in the absence of a clinical or radiological progression disease, to anticipate a change of treatment with bevacizumab plus FOLFIRI further impacts on the PFS.

NCT Number	NCT04776655
Lead Sponsor	Azienda USL Reggio Emilia - IRCCS Collaborators: Istituto Di Ricerche Farmacologiche Mario Negri, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Conditions	Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation
Enrollment	280 participants
Start Date	2021-04-30
Primary Completion	2025-05-04 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-24